Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that it will present at the 2008 UBS Global Life Sciences Conference on Wednesday, September 24, 2008 at 4:00 p.m. Eastern Time. Russell Howard, Maxygen’s chief executive officer, will present. A live webcast of the presentation can be accessed on Maxygen’s website at www.maxygen.com/webcasts. A replay of the presentation will be available for 30 days.

About Maxygen

Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. The company’s lead program, MAXY-G34, is designed to be an improved long-acting G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Maxygen also has a MAXY-4 program, under which it is exploring new CTLA4-Ig product candidates for the treatment of a broad array of autoimmune disorders and transplantation rejection. Maxygen uses its proprietary DNA shuffling technology and extensive protein modification expertise to pursue the creation of biosuperior proteins. www.maxygen.com

Maxygen, Inc.
Michele Boudreau, 650-279-2088
Investor and Public Relations
michele.boudreau@maxygen.com